heart valve repair hybrid or cath lab structural heart tct medtronic corevalve

In a clinical trial, a self-expanding transcatheter aortic valve met the key performance objective of reducing death and stroke in patients with severe aortic stenosis at “extreme risk” for surgery. Results of the CoreValve Extreme Risk trial were presented at the 25th annual Transcatheter Cardiovascular Therapeutics scientific symposium (TCT 2013) in San Francisco.
stents biforcation clinical trial study cath lab tryton tct side branch

Tryton Medical Inc., a developer of stents designed to treat bifurcation lesions, announced activities highlighting the latest data and experience with the Tryton Side Branch Stent at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium (TCT 2013).
cath lab tct advanced visualization hybrid or philips realview holographic 3-D

Philips and RealView Imaging Ltd. have completed a clinical study that demonstrated the feasibility of using an innovative live 3-D holographic visualization and interaction technology to guide minimally invasive structural heart disease procedures.
heart valve repair hybrid or cath lab

Boston Scientific Corp. has received CE mark for its Lotus Valve System, a transcatheter aortic valve replacement (TAVR) technology. This key approval offers an effective new treatment alternative for patients with severe aortic stenosis at high risk with surgical valve replacement.

St. Jude Medical Inc. announced positive results for the 23 and 25mm Portico Transcatheter Aortic Heart Valves in the Portico Transfemoral CE mark trial (Portico TF CE Trial). Patients enrolled in the study experienced a significant improvement in valve function at 30 days. 

Patients treated with the Boston Scientific Vessix Renal Denervation System experienced a significant and sustained reduction in blood pressure, according to new data presented today at the Transcatheter Cardiovascular Therapeutics Conference (TCT 2013) in San Francisco. An interim analysis of 139 patients enrolled in the REDUCE-HTN post market study affirms the device safety profile and effective treatment for resistant hypertension.

Abbott announced it plans to initiate a randomized, controlled trial in the United States to evaluate the use of dual anti-platelet therapy (DAPT) for a three-month duration following treatment with the company's Xience family of drug eluting stents (DES). 

Amaranth Medical, a privately held medical device company, presented positive six-month angiographic results from its first-in-human study including patients undergoing percutaneous coronary intervention (PCI) with single coronary lesions. 

medtronic corevalve cath lab hybrid or heart valve repair study TCT 2013

The CoreValve U.S. pivotal trial showed very positive results for the Medtronic CoreValve system, comparable or better than data from the Sapien Partner Trial.

Terumo Interventional Systems announced the launch of the 0.018-inch Glidewire Advantage peripheral guidewire during the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now